Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false and misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, based on data from the Sierra Trial [4]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, leading to a probable refusal to review or approve the BLA [4]. Group 3: Impact on Stock Price - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, falling $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against The Bancorp, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 16, 2025 [3][11]. Group 1: Allegations Against The Bancorp - The complaint alleges that The Bancorp and its executives made false or misleading statements regarding the risks associated with its REBL loan portfolio, including underrepresenting the risk of default [5]. - It is claimed that the company's expected credit loss methodology was inadequate, leading to a likely increase in provisions for credit losses [5]. - The company reportedly had material weaknesses in its internal controls over financial reporting, and its financial statements were not approved by independent auditors, making them unreliable [5]. Group 2: Market Reactions and Financial Disclosures - Following a report from Culper Research on March 21, 2024, alleging significant risks in the company's loan portfolio, The Bancorp's share price fell by $3.63, or 10.15%, closing at $32.12 [7]. - On October 24, 2024, the company reported a net income of $51.5 million for Q3 2024, but this included a $1.5 million reduction due to increased provisions for credit losses, leading to a share price drop of $7.95, or 14.47%, to $47.01 [8]. - On March 4, 2025, The Bancorp disclosed that its financial statements for fiscal years 2022 to 2024 should no longer be relied upon, resulting in a share price decline of $2.34, or 4.38%, to $51.25 [9][10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Everus Construction Group, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's backlog and revenue recognition [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Everus between October 31, 2024, and February 11, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Everus, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3][7]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Everus - The complaint alleges that Everus and its executives made false or misleading statements regarding the company's backlog conversion cycle, which has become elongated due to larger and more complex projects [5]. - As a result of the backlog issues, the company's revenue recognition is expected to be delayed, contradicting previous positive statements about its business prospects [5]. - Following the release of its fourth-quarter and full-year 2024 financial results, Everus's stock price fell by $18.88, or 27.6%, over two trading days, closing at $49.54 on February 13, 2025 [6]. Group 3: Financial Performance and Future Outlook - Everus projected revenue for 2025 in the range of $3.0 billion to $3.1 billion and EBITDA between $210 million and $225 million, citing changes in the composition of its backlog [6]. - The company indicated that the average project size has been increasing, leading to a longer backlog conversion cycle [6].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][4][7]. Group 1: Legal Allegations - The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts during Cerevel's secondary stock offering on October 16, 2023, where shares were sold at $22.81 [6]. - Bain Capital is accused of acquiring Cerevel shares while allegedly possessing nonpublic information about AbbVie's interest in acquiring the company, which was later disclosed at a price of $45 per share [6][7]. - The January 18, 2024, Proxy statement regarding the AbbVie acquisition is claimed to have misled investors about the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [6][7]. Group 2: Class Action Details - Investors who sold or disposed of Cerevel stock between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, may have been damaged by the defendants' actions and are encouraged to contact the law firm for legal options [1][4]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action is June 3, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

Core Insights - Holzer & Holzer, LLC is investigating TechTarget, Inc. for potential non-compliance with federal securities laws following the announcement of accounting errors in previously issued financial statements [1] - The announcement led to a decline in TechTarget's stock price [1] Company Summary - TechTarget, Inc. is facing scrutiny due to accounting errors related to the Informa Tech Digital Businesses of Informa PLC, which has raised concerns about the reliability of its financial statements [1] - The investigation by Holzer & Holzer, LLC indicates potential legal implications for TechTarget and its shareholders [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fluence To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Fluence between November 29, 2023 to February 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Fa ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements about the company's financial health and product development [3][5]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Sana between March 17, 2023, and November 4, 2024, to discuss their legal rights [1][3]. - A federal securities class action has been filed against Sana, with a deadline of May 20, 2025, for investors to seek the role of lead plaintiff [3][9]. - The complaint alleges that Sana and its executives made false statements about the company's financial capacity and the potential of its product candidates [5]. Group 2: Company Financials and Operations - On October 10, 2023, Sana announced a strategic shift to reduce spending on its fusogen platform and focus on its ex vivo cell therapy platform, resulting in a 29% headcount reduction [6][7]. - Following this announcement, Sana's stock price fell by $0.34 per share, or 8.95%, closing at $3.46 per share on October 11, 2023 [7]. - On November 4, 2024, Sana suspended development of SC291 and SC379, reallocating resources to its type 1 diabetes program, which extended its cash runway into 2026 [8]. - After this announcement, Sana's stock price dropped by $0.37 per share, or 9.84%, closing at $3.39 per share on November 5, 2024 [8].